#ScienceLink #Madrid2026 #ESMO26
Dra. Isabel Enríquez（🇲🇽）和 Dr. Julio Velasco（🇲🇽）分析了我们报道首集的证据：
🔎 早期胃肠道肿瘤：辅助化疗（QT）减量、主动监测及新辅助免疫治疗，采用 LOMAC、SANO 和 GERCOR-GONO DEWI。
🧬 晚期胃肠道疾病：HERIZON-GEA-01、RAMIRIS 和 G-HOPE-001 中的新组合和靶向治疗。
📊 乳腺癌：NATALEE 6 年总生存（SG），NSABP B-42 15 年随访及 DESTINY-Breast05 的生活质量。
🎯 BRAF V600 黑色素瘤：STARBOARD 中 encorafenib + binimetinib + pembrolizumab 三联疗法的结果。
⏳ 广泛期 CPCP：DeLLphi-305 以及 tarlatamab 联合 durvalumab 作为维持治疗。单用 durvalumab 的中位总生存（SG）为 21.1 对 12.7 个月（HR 0.42），从随机分组至维持治疗测量。
🎙️收听完整节目：https://buff.ly/CcXhP2o
7 浏览 · 0 赞 · 0 转发 · 0 回复
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.orgSustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgPatient (pt)-reported outcomes (PROs) from the Phase III lidERA Breast Cancer (BC) trial of giredestrant (GIRE) in pts with oestrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC)
https://esmocongress.esmo.org来源：ScienceLink · x.com